Last reviewed · How we verify
NCT04201730
Study on the Efficacy and Safety of Enhanced Recovery After Surgery （ERAS）in Gastrointestinal Cancer
NA trial testing Enhanced Recovery After Surgery （ERAS） in Enhanced Recovery After Surgery in 356 participants. Completed in 1 June 2021.
31 December 2020
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 356 |
| Start date | 25 December 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Enhanced Recovery After Surgery （ERAS）
Conditions studied
- Enhanced Recovery After Surgery — all drugs for Enhanced Recovery After Surgery →
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Sponsor
Huashan Hospital
Who can join
Adults 18 to 70, any sex, with Enhanced Recovery After Surgery or Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, there are more and more reports about enhanced recovery after surgery（ERAS）in China, but there is no ERAS treatment standard for gastrointestinal cancer, and there are many factors limiting the development of ERAS. In recent years, due to the development of minimally invasive technology, the establishment of evidence-based medicine model and the development of MDT, it makes a good solid foundation for the clinical application of ERAS. The implementation of ERAS requires the cooperation of surgeons, anesthesia management, nursing, rehabilitation and other teams. As an individualized treatment mode, ERAS focuses on the optimization of treatment for different individuals in order to acquire the best benefit of patients. Therefore, the concept of ERAS is still in the process of continuous improvement and development in China, hoping to explore the Chinese ERAS clinical pathway for gastrointestinal cancer. The purpose of this study is to optimize the clinical pathway of ERAS in the perioperative period of gastrointestinal cancer, and to evaluate the effectiveness and safety of ERAS in gastrointestinal cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.
Cencioni C, Trestini I, Piro G, Bria E, et al · · 2022 · cited 24× · PMID 35458104 · DOI 10.3390/nu14081542
Verify or expand the search:
- PubMed search for NCT04201730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Enhanced Recovery After Surgery
Currently open trials in the same condition.
- NCT06984952 — Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy · NA · recruiting
- NCT06920576 — Effects of Esketamine Versus Magnesium Sulfate on Emotional State and Postoperative Pain in Patients Undergoing Nasal En · Phase 1, PHASE2 · active not recruiting
- NCT06719492 — Nutrition Education in Spine Surgery · NA · active not recruiting
- NCT06457100 — Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Sur · Phase 1, PHASE2 · active not recruiting
- NCT06369194 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol · active not recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04201730 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 21 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04201730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing